Year: 2015
Type: article
Study design: Observational Study
Abstract: Glucagon-like peptide 1 (GLP-1) induces insulin secretion and proliferation of pancreatic β-cells, and inhibits their apoptosis through the GLP-1 receptor (GLP-1R), thus providing a foundation for using GLP-1-based therapies for the treatment of type 2 diabetes. However, doubts have emerged regarding the drug safety of these therapies. We investigated the potential role of GLP-1R in pancreatic ductal adenocarcinoma (PDAC). GLP-1R expression was semi-quantitatively evaluated by immunohistochemistry in 48 PDAC samples, and its correlations with clinicopathological features were investigated. CFPAC-1 cells were used for GLP-1R knockdown to evaluate its effects on cell proliferation, migration and invasion. GLP-1R expression was positive in 23 tumors and negative in 25 tumors. No correlations were found between GLP-1R expression status and clinicopathological characteristics. Furthermore, GLP-1R expression status did not affect the patient prognosis (P=0.74). The majority of lymph node metastases (11 of 15 samples examined; 73%) were positive for GLP-1R expression. Immunoreactivity for GLP-1R was also noted in sites of perineural and lymphovascular invasion. GLP-1R knockdown significantly reduced the proliferation, migration and invasion of CFPAC-1 cells (P<0.05). In conclusion, although GLP-1R is not an independent prognostic factor in PDAC patients, it appears to have some implications for PDAC metastatic ability.
Source: Oncology Reports
DOI: 10.3892/or.2015.4138
Institution: Kyushu University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Application of GLP-1 on the treatment of pancreatic cancer, Identifying the leading cell for the invasion of pancreatic cancer, Identification of the key stromal cell responsible for desmoplasia of pancreatic cancer, elucidation of the origin of it, and regulation of its function, Elucidation of leading cell and cancer microenvironment normalization of pancreatic cancer, G4855473883, G5688495541, Early detection of pancreatic ductal adenocarcinoma based on the molecular assessment of pancreatic ductal adenocarcinoma concomitant with IPMN of the pancreas.
OpenAlex ID: W2143892050